Search results for "CHRONIC DISEASE"

showing 10 items of 792 documents

Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2.

1999

1. Cacospongionolide B is a novel marine metabolite isolated from the sponge Fasciospongia cavernosa. In in vitro studies, this compound inhibited phospholipase A2 (PLA2), showing selectivity for secretory PLA2 (sPLA2) versus cytosolic PLA2 (cPLA2), and its potency on the human synovial enzyme (group II) was similar to that of manoalide. 2. This activity was confirmed in vivo in the 8 h zymosan-injected rat air pouch, on the secretory enzyme accumulating in the pouch exudate. Cacospongionolide B, that is bioavailable when is given orally, reduced the elevated levels of sPLA2 present in paw homogenates of rats with adjuvant arthritis. 3. This marine metabolite showed topical anti-inflammator…

InflammationMaleDose-Response Relationship DrugEarU937 CellsArthritis ExperimentalPhospholipases AEnzymesRatsMicePhospholipases A24-ButyrolactoneAnti-Infective AgentsAcute DiseaseChronic DiseaseSynovial FluidPapersLeukocytesAnimalsEdemaHumansFemaleRats WistarPyransBritish journal of pharmacology
researchProduct

Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

2022

Objective: The aim was to assess the awareness and real-life use of biosimilars in inflammatory bowel disease (IBD) among the members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Methods: An anonymous web survey involving all SIGENP IBD units which can prescribe biosimilars was conducted between July 1st and December 1st, 2020. The questionnaire included 18 questions addressing the most relevant aspects of biosimilars in pediatric IBD, i.e., advantages, disadvantages, costs, traceability, general knowledge, and real-life use. A descriptive analysis of responses was performed. Results: Responses came from 26 pediatric IBD units in Italy, with repre…

Inflammatory Bowel Diseasesbiosimilars; inflammatory bowel disease; childrendigestive system diseasesChild; Chronic Disease; Humans; Surveys and Questionnaires; Biosimilar Pharmaceuticals; Inflammatory Bowel DiseasesSurveys and QuestionnairesPediatrics Perinatology and Child HealthChronic DiseaseSurveys and QuestionnaireHumansPharmacology (medical)ChildBiosimilar PharmaceuticalsHumanBiosimilar Pharmaceutical
researchProduct

Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

1992

The phosphodiesterase inhibitors have been recognised as potent inotropic and vasodilating drugs. In acute congestive heart failure they increase cardiac output, decrease left pulmonary capillary wedge pressure, and reduce total peripheral resistance with an improvement in loading conditions of the failing heart. Their potency in reversal of symptoms of acute congestive heart failure is quite similar to, or even better than, treatment with intravenous catecholamines and sodium nitroprusside. In chronic congestive heart failure, however, these agents increase mortality and have deleterious effects in the outcome of patients with severe left ventricular dysfunction.

InotropeHeart Failuremedicine.medical_specialtybusiness.industryPhosphodiesterase InhibitorsVasodilationmedicine.diseaseCardiovascular SystemAmrinoneEndocrinologyPimobendanInternal medicineHeart failureAcute DiseaseChronic DiseasemedicineCardiologyMilrinoneEnoximoneHumansPharmacology (medical)Pulmonary wedge pressurebusinessmedicine.drugDrugs
researchProduct

Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection.

2010

Th1 CD4(+) T cells and their derived cytokines are crucial for protection against Mycobacterium tuberculosis. Using multiparametic flow cytometry, we have evaluated the distribution of seven distinct functional states (IFN-gamma/IL-2/TNF-alpha triple expressors, IFN-gamma/IL-2, IFN-gamma/TNF-alpha or TNF-alpha/IL-2 double expressors or IFN-gamma, IL-2 or TNF-alpha single expressors) of CD4(+) T cells in individuals with latent M. tuberculosis infection (LTBI) and active tuberculosis (TB). We found that triple expressors, while detectable in 85-90%TB patients, were only present in 10-15% of LTBI subjects. On the contrary, LTBI subjects had significantly higher (12- to 15-fold) proportions of…

Interleukin 2AdultCD4-Positive T-LymphocytesMaleTuberculosisSettore MED/17 - Malattie InfettiveImmunologyCell SeparationBiologyLymphocyte ActivationFlow cytometryMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineImmune systemBacterial ProteinsCD4(+) T cells Cytokines Mycobacterium tuberculosis infection Tuberculosis disease interferon-gamma immunological memory disease responses protection cytokine immunity bcg vaccination virusmedicineImmunology and AllergyDistribution (pharmacology)HumansCytokineTuberculosis Pulmonary030304 developmental biologyTuberculosis disease.Settore MED/04 - Patologia Generale0303 health sciencesAntigens Bacterialmedicine.diagnostic_testMycobacterium tuberculosis infectionMycobacterium tuberculosisMiddle Agedbiology.organism_classificationmedicine.diseaseFlow CytometryPhenotypeVirologyCD4+ T cellsBacterial Load3. Good healthImmunologyAcute DiseaseChronic DiseaseCytokinesTumor necrosis factor alphaAcyltransferases030215 immunologymedicine.drugEuropean journal of immunology
researchProduct

Differential expression patterns of cytokines in complex regional pain syndrome.

2007

Complex regional pain syndromes (CRPS) are characterized by persistent and severe pain after trauma or surgery. Neuro-immune alterations are assumed to play a pathophysiological role. Here we set out to investigate whether patients with CRPS have altered systemic pro- and anti-inflammatory cytokine profiles compared to controls on mRNA and protein level. We studied blood cytokine mRNA and protein levels of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin-2 (IL-2) and IL-8 and the anti-inflammatory cytokines IL-4, IL-10, and transforming growth factor-beta1 (TGF beta 1) in 40 prospectively recruited patients with CRPS I, two patients with CRPS II, and 34 controls…

Interleukin 2AdultMalemedicine.medical_specialtyNeuroimmunomodulationmedicine.medical_treatmentInternal medicinemedicineHomeostasisHumansTGF beta 1Agedbiologybusiness.industryChronic painModels ImmunologicalMiddle Agedmedicine.diseasePathophysiologyImmunity InnateAnesthesiology and Pain MedicineCytokineComplex regional pain syndromeEndocrinologyNeurologyGene Expression RegulationMcGill Pain QuestionnaireChronic Diseasebiology.proteinCytokinesTumor necrosis factor alphaFemaleNeurology (clinical)businessComplex Regional Pain Syndromesmedicine.drugPain
researchProduct

Characterization of disease-specific cellular abundance profiles of chronic inflammatory skin conditions from deconvolution of biopsy samples

2019

Background Psoriasis and atopic dermatitis are two inflammatory skin diseases with a high prevalence and a significant burden on the patients. Underlying molecular mechanisms include chronic inflammation and abnormal proliferation. However, the cell types contributing to these molecular mechanisms are much less understood. Recently, deconvolution methodologies have allowed the digital quantification of cell types in bulk tissue based on mRNA expression data from biopsies. Using these methods to study the cellular composition of the skin enables the rapid enumeration of multiple cell types, providing insight into the numerical changes of cell types associated with chronic inflammatory skin c…

Keratinocytes0301 basic medicinePathologyMicroarraysBiopsyPATHOGENESISTranscriptome0302 clinical medicineDatabases GeneticLeukocytesATOPIC-DERMATITISGenetics (clinical)SkinPSORIASISmedicine.diagnostic_testintegumentary systemAtopic dermatitisDermismedicine.anatomical_structureDIFFERENTIATION030220 oncology & carcinogenesisChronic inflammatory skin diseasesResearch ArticleEXPRESSIONlcsh:Internal medicinemedicine.medical_specialtyCell typeGENESlcsh:QH426-470BiologyDENDRITIC CELLSDermatitis AtopicFlow cytometryMECHANISMS03 medical and health sciencesDermisPsoriasisBiopsyGeneticsmedicineHumanslcsh:RC31-1245SIGNATURESInflammationIDENTIFICATIONReproducibility of Resultsmedicine.diseaselcsh:Genetics030104 developmental biologyGene Expression RegulationChronic DiseaseSkin biopsyGene expressionEpidermis
researchProduct

Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of …

2018

PurposeTo compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT).MethodsThis is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m2) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm.ResultsIn the MP group, at 12 months of follow-up, the mean best corr…

Laser surgeryMaleFluorescein angiographyretinaVisual acuityoptical coherencegenetic structuresPhysiologymedicine.medical_treatmentCentral serous chorioretinopathyVisual AcuityPhotodynamic therapytreatment lasersProceduresPhotodynamic therapychemistry.chemical_compound0302 clinical medicineBest corrected visual acuityMedicineFluorescein AngiographyTreatment outcomeMiddle agedTomographyPriority journalLow level laser therapyPhotosensitizing Agentsmedicine.diagnostic_testMiddle AgedFluorescein angiographyVerteporfinPhotosensitizing agentsSensory SystemsIndocyanine greenMulticenter studyBevacizumabClinical trialRetrospective studyTreatment OutcomeCentral Serous ChorioretinopathyFemaleLaser Therapymedicine.symptomTomography Optical Coherencemedicine.drugHumanIndocyanine GreenAdultmedicine.medical_specialtyVisual acuityLaser surgeryMajor clinical studyFollow-up studiesPathophysiologyArticleChronic disease03 medical and health sciencesCellular and Molecular NeuroscienceLaser therapyOphthalmologyFluorescence angiographyHumansmaculaLow level laser therapyRetrospective StudiesDisease durationPhotosensitizing agentOptical coherence tomographybusiness.industryIntermethod comparisonSubretinal neovascularizationCentral serous retinopathyVerteporfinFollow upmedicine.diseaseMulticenter study (topic)eye diseasesRetrospective studiesOphthalmologyCentral serous retinopathychemistryPhotochemotherapyChronic Disease030221 ophthalmology & optometryYellow micropulse laserComparative studysense organsbusinessIndocyanine greenControlled study030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Leptin: A pivotal mediator of intestinal inflammation in mice

2002

Abstract Background & Aims: In addition to acting as a regulator of food intake and energy expenditure, leptin can also modulate immune and inflammatory responses. The role of leptin in intestinal inflammation is the focus of the present study. Methods: Acute and chronic colitis were induced in leptin-deficient ob/ob or wild-type (WT) mice using dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS). The severity of colitis was evaluated, and possible mechanisms were studied. Results: Leptin directly stimulates intraepithelial lymphocytes (IELs) and lamina propria mononuclear cells (LPMCs). In the DSS acute model, ob/ob mice exhibited a 72% reduction of colitis severity and sp…

LeptinSTAT3 Transcription Factormedicine.medical_specialtyColonanimal diseasesdigestive systemMonocytesProinflammatory cytokineMiceReference ValuesInternal medicinemedicineAnimalsInterferon gammaLymphocytesObesityIntestinal MucosaColitisMacrophage inflammatory proteinCells CulturedLeptin DeficiencyHepatologybusiness.industryLeptinDextran SulfateGastroenterologyColitismedicine.diseasedigestive system diseasesDNA-Binding ProteinsIsoenzymesMice Inbred C57BLEndocrinologyTrinitrobenzenesulfonic AcidCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme InductionChronic DiseaseImmunologyTrans-ActivatorsCytokinesIntraepithelial lymphocyteFemaleTumor necrosis factor alphaDisease SusceptibilityChemokinesbusinessmedicine.drugGastroenterology
researchProduct

Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the…

2020

Abstract Background The COVID-19 pandemic had a huge impact on national and regional health systems. The impact of SARS-CoV-2 on the quality of care for patients with liver disease is still unknown. Aims The Italian Association for the Study of the Liver (AISF) conducted a survey to assess the impact of SARS-CoV-2 on hepatology units activities in Italy. Methods A prospective web-based survey was proposed to all AISF active members. The survey was available online from April 8 2020, to May 3 2020, (lockdown phase in Italy). Results 194 AISF members answered the questionnaire, most of whom were specialists in Gastroenterology (41%) or Internal Medicine (28%), and worked in Northern Italy (51…

Liver CirrhosisLiver disease0302 clinical medicineSurveys and QuestionnairesPandemicAmbulatory CareMass ScreeningParacentesisViralChronicLiver DiseasesLiver NeoplasmsGastroenterologyHepatology Covid-19 SARS COV-2Hepatitis BHepatitis CHospitalizationCovid-19; Hepatology; SARS COV-2Italy030220 oncology & carcinogenesis030211 gastroenterology & hepatologyCoronavirus Infectionsmedicine.medical_specialtyCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralEsophageal and Gastric VaricesAntiviral AgentsArticle03 medical and health sciencesBetacoronavirusHepatitis B ChronicInternal medicinemedicineHumansPandemicsMass screeningQuality of Health CareHepatologybusiness.industrySARS-CoV-2SARS COV-2CarcinomaOutbreakCOVID-19HepatocellularPneumoniaHepatitis C ChronicHepatologymedicine.diseaseNorthern italyLiver TransplantationEmergency medicineChronic DiseaseCovid-19; Hepatology; SARS COV-2; Ambulatory Care; Antiviral Agents; Betacoronavirus; COVID-19; Carcinoma Hepatocellular; Chronic Disease; Coronavirus Infections; Esophageal and Gastric Varices; Gastroenterology; Hepatitis B Chronic; Hepatitis C Chronic; Hospitalization; Humans; Italy; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Liver Transplantation; Mass Screening; Pandemics; Paracentesis; Pneumonia Viral; Quality of Health Care; SARS-CoV-2; Surveys and Questionnairesbusiness
researchProduct

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

2012

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…

Liver CirrhosisMaleCirrhosisChronic liver diseaseBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawReceptorsClinical endpoint80 and overMedicineCIRRHOSISAged 80 and overBenzoic AcidsGeneral MedicineCHRONIC LIVER DISEASEMiddle AgedHydrazinesThrombopoietinElective Surgical ProceduresAnesthesiaFemaleElective Surgical ProcedureReceptors ThrombopoietinAdultAdolescentEltrombopagELTROMBOPAGHemorrhagePlatelet TransfusionPlaceboYoung AdultDouble-Blind MethodElectiveSurgical Procedures ElectiveHumansAgedTHROMBOCYTOPENIA; ELTROMBOPAG; CIRRHOSIS; CHRONIC LIVER DISEASESurgical Proceduresbusiness.industryPlatelet CountTHROMBOCYTOPENIAcirrhosisSettore MED/09 - MEDICINA INTERNAmedicine.diseaseThrombocytopeniaPlatelet transfusionchemistryChronic DiseasePyrazolesbusiness
researchProduct